GRAIL’s Galleri blood test hints it could catch more cancers earlier, but recent trial results and slow insurance coverage raise questions about how quickly it can become a routine screening option. The big swing factor is whether regulators and health systems turn today’s mixed evidence into broad adoption before costs and other obligations weigh on progress.Read more
A new Medicare route and big real-world trials could make Grail’s Galleri blood test easier for doctors and insurers to use, pushing multi-cancer screening beyond today’s early adopters. But the key study result is mixed and the company still burns a lot of cash, so the path to wider coverage and sustainable growth may be bumpier than it looks.Read more
GRAIL is pushing its Galleri blood test from promising study results into wider real-world use through big health and testing partners, which could open the door to broader insurance coverage and approvals. But the company is still losing a lot of money and faces regulatory, pricing, and competition risks that could slow its path to becoming a durable business.Read more
No trending discussion available.
GRAIL, Inc., a commercial-stage healthcare company, provides multi-cancer early detection testing and services in the United States and internationally. It offers Galleri, a cancer screening test for asymptomatic individuals over 50 years of age; and a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients with clinical suspicion of cancer. The company also provides development services, including support for ongoing clinical studies, pilot testing, research, and therapy development. In addition, its precision oncology portfolio consists of n RUO-targeted methylation-based platform that enables applications for disease prognostication, risk stratification, minimal residual disease detection, and recurrence and relapse monitoring. The company was incorporated in 2015 and is headquartered in Menlo Park, California.
